MiNK Therapeutics, Inc.
INKT
$8.41
-$0.34-3.89%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 4.31M | 5.69M | 6.33M | 7.05M | 7.43M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | 118.20K | 180.90K | -- | -- | -- |
Total Operating Expenses | 12.98M | 14.12M | 17.46M | 20.90M | 22.92M |
Operating Income | -12.98M | -14.12M | -17.46M | -20.90M | -22.92M |
Income Before Tax | -10.78M | -13.78M | -17.09M | -20.59M | -22.46M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -10.78 | -13.78 | -17.09 | -20.59 | -22.46 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -10.78M | -13.78M | -17.09M | -20.59M | -22.46M |
EBIT | -12.98M | -14.12M | -17.46M | -20.90M | -22.92M |
EBITDA | -12.71M | -13.90M | -17.25M | -20.68M | -22.72M |
EPS Basic | -2.91 | -3.86 | -4.89 | -5.96 | -6.54 |
Normalized Basic EPS | -2.11 | -2.45 | -3.09 | -3.73 | -4.09 |
EPS Diluted | -3.53 | -3.86 | -4.89 | -5.96 | -6.56 |
Normalized Diluted EPS | -2.11 | -2.45 | -3.09 | -3.73 | -4.09 |
Average Basic Shares Outstanding | 15.09M | 14.59M | 14.08M | 13.81M | 13.74M |
Average Diluted Shares Outstanding | 15.09M | 14.59M | 14.08M | 13.81M | 13.74M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |